Baseline characteristics
| Women (n=98) | Men (n=176) | p Value | |
| Age, mean (SD) | 70.2 (10.7) | 63.9 (12.0) | <0.001 |
| ECG on admission | |||
| ST-elevation on admission ECG (%) | 89 (90.8) | 160 (90.9) | 0.98 |
| Bundle branch block on admission ECG (%) | 6 (6.1) | 11 (6.3) | 0.97 |
| Other admission ECG (%) | 3 (3.1) | 5 (2.8) | 0.92 |
| Comorbidity | |||
| Active smoker (%) | 31 (32.0) | 49 (28.3) | 0.53 |
| Diabetes (%) | 20 (20.4) | 31 (17.6) | 0.57 |
| Hypertension (%) | 56 (57.7) | 60 (34.5) | <0.001 |
| Chronic obstructive pulmonary disease (%) | 17 (17.9) | 14 (8.0) | 0.02 |
| Previous MI (%) | 14 (14.3) | 34 (19.3) | 0.29 |
| Previous PCI (%) | 10 (10.2) | 29 (16.5) | 0.15 |
| Previous coronary artery bypass grafting (%) | 2 (2.0) | 7 (4.0) | 0.39 |
| Previous stroke (%) | 10 (10.2) | 14 (8.0) | 0.53 |
| Previous heart failure (%) | 8 (8.4) | 8 (4.6) | 0.21 |
| Previous hospital diagnosis of cancer within the past 3 years (%) | 3 (3.2) | 7 (4.0) | 0.72 |
| Kidney function | |||
| Creatinine, mean (SD) | 99 (24) | 105 (18) | 0.03 |
| eGFR in ml/min on arrival, mean (SD) | 54 (13) | 68 (13) | <0.001 |
| CKD stage 1, eGFR ≥90 l/min (%) | 0 (0) | 10 (5.7) | <0.001 |
| CKD stage 2, eGFR 60–89 ml/min (%) | 32 (33.3) | 118 (67.8) | |
| CKD stage 3a, eGFR 45–59 ml/min (%) | 47 (49.0) | 39 (22.4) | |
| CKD stage 3b, eGFR 30–44 ml/min (%) | 12 (12.5) | 6 (3.4) | |
| CKD stage 4, eGFR 15–29 ml/min (%) | 5 (5.2) | 1 (0.6) | |
| CKD stage 5, eGFR <15 ml/min (%) | 0 (0) | 0 (0) | |
| Delay times | |||
| Symptom to ECG time, median (25th, 75th percentile) | 125 (69, 240) | 117 (56, 249) | 0.64 |
| Symptom to needle time, median (25th, 75th percentile) | 221 (155, 379) | 211 (143, 378) | 0.59 |
| Killip class on admission | |||
| Killip class I on admission (%) | 83 (84.7) | 163 (92.6) | 0.15 |
| Killip class II on admission (%) | 7 (7.1) | 6 (3.4) | |
| Killip class III on admission (%) | 1 (1.0) | 0 (0) | |
| Killip class IV on admission (%) | 7 (7.1) | 7 (4.0) | |
| Therapy on admission | |||
| Angiotensin receptor inhibitor/angiotensin II receptor blocker (%) | 19 (19.4) | 39 (22.2) | 0.59 |
| Aspirin (%) | 35 (35.7) | 42 (23.9) | 0.04 |
| Clopidogrel/other non-acetylsalicylic acid platelet inhibitor (%) | 7 (7.1) | 7 (4.0) | 0.25 |
| Warfarin/other anticoagulant drug (%) | 8 (8.2) | 8 (4.5) | 0.22 |
| β-blocker (%) | 39 (39.8) | 55 (31.3) | 0.15 |
| Calcium antagonist (%) | 15 (15.3) | 16 (9.1) | 0.12 |
| Statin (%) | 19 (19.4) | 39 (22.2) | 0.59 |
| Diuretic (%) | 36 (36.7) | 22 (12.5) | <0.001 |
| Digitalis (%) | 6 (6.1) | 3 (1.7) | 0.05 |
| Long-acting nitrates (%) | 13 (13.3) | 12 (6.8) | 0.08 |
Data presented as numbers (percentages) if not otherwise indicated.
MI, myocardial infarction; PCI, percutaneous coronary intervention; eGFR, estimated glomerular filtration rate; CABG, coronary artery bypass grafting.